FLT3 inhibitors in AML: Current clinical landscape and key insights from trials
The AML Hub was pleased to speak with Mark J. Levis, Johns Hopkins University, Baltimore, US. We asked, What is the current clinical landscape of FLT3 inhibitors in the treatment of AML, and what insi...
1 Heinä 4min
Future directions for FLT3 inhibitors in AML treatment
The AML Hub was pleased to speak with Eytan Stein, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What might the future hold for the evolution of FLT3 inhibitors in the treatment of A...
30 Kesä 4min
Key questions in FLT3-mutated AML, and ongoing research to address these
The AML Hub was pleased to speak with Charles Craddock, Queen Elizabeth Hospital Birmingham, Birmingham, UK. We asked, What are the key ongoing questions in FLT3-mutated AML, and how are ongoing trial...
26 Kesä 5min
Menin inhibitors in AML: Where are we now, and where are we going?
During a meeting of the AML Hub Steering Committee, held on February 19, 2026, Jorge Cortes chaired a discussion on the topic, Menin inhibitors in AML: Where are we now, and where are we going? The di...
22 Touko 30min
Managing side effects of menin inhibitors in clinical practice
The AML Hub was pleased to speak with Gail Roboz, Weill Cornell Medicine, New York, US. We asked, What side effects are typically observed with menin inhibitor-based regimens, and how do you approach ...
21 Touko 7min
Treatment decisions in AML: Personalizing care with FLT3 inhibitor therapy
During a meeting of the AML Hub Steering Committee, held on February 19, 2026, Jorge Sierra chaired a discussion on the topic, Treatment decisions in acute myeloid leukemia (AML): Personalizing care w...
19 Touko 32min
What key insights are emerging from ongoing trials of menin inhibitor combination strategies in AML?
The AML Hub was pleased to speak with Joshua Zeidner, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, US. We asked, What key insights are emerging from ongoing trials...
15 Touko 5min
